

Arghavan Hajsheykholeslami

Tehran, Iran

Phone: +98 21-86703454

hajsheykholeslami.a@iums.ac.ir

PROFESSIONAL EXPERIENCE

- **Assistant Professor** 2019 - Present
Public Health and Community Medicine department
Preventive Medicine and Public Health Research Center
Iran University of Medical Sciences
- **Research Fellow** 2004 - 2014
Digestive Disease Research Center (DDRC)
Shariati Hospital
Research focus on Helicobacter Pylori and Hepatitis C

EDUCATION

- **Doctor of Medicine** 1995 - 2003
Tehran Azad University of Medical Sciences
- **Community Medicine and Public Health Residency** 2014 - 2018
Iran University of Medical Sciences

AWARDS & HONORS

First rank in national community medicine board exam 2018

Skills

- Languages:
 - Farsi (Native Speaker)
 - English (advanced)
Ministry of Health and Medical Education's English Language Exam (MHLE)
score 93/100 in 2014)
- Computer
 - Microsoft Office
 - SPSS

Publications

1. Babae E, Tehrani-Banihashem A, Asadi-Aliabadi M, Sheykhholeslami A, Purabdollah M, Ashari A, et al. Population-based approaches to prevent domestic violence against women using a systematic review. *Iranian journal of psychiatry*. 2021;16(1):94.
2. Soroush Z, Sajadi F, Tapehsari BS, Haj-Sheykholeslami A. High-risk behaviors in medical students: a cross-sectional study from Tehran, Iran. *Modern Care Journal*. 2018;15(3).
3. Moayedi J, Hashempour T, Musavi Z, Hallaji M, Ghasabi F, Haj-Sheykholeslami A, et al. Comparison of IL-28B favorable genotype frequency between healthy and patients infected with HCV. *scientific journal of ilam university of medical sciences*. 2018;26(2):28-36.
4. Hashempour T, Alborzi AM, Moayedi J, Ajorloo M, Bamdad T, Sharifi AH, et al. A decline in anti-core+ 1 antibody titer occurs in successful treatment of patients infected with hepatitis C virus. *Jundishapur Journal of Microbiology*. 2018;11(2).
5. Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B, Nateghi-Baygi A, et al. The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3. *Hepatitis Monthly*. 2017;17(1):4.
6. Sharifi A, Haj-Sheykholeslami A, Poustchi H, Golzari R, Merat S, Malekzadeh R, et al. Efficacy of locally manufactured sofosbuvir and daclatasvir (Sovodak) in combination with ribavirin in treating patients with chronic hepatitis c and cirrhosis in Iran—preliminary report. *Govaresh*. 2016;21(2):93-7.
7. Massarrat S, Haj-Sheykholeslami A. Increased serum pepsinogen II level as a marker of pangastritis and corpus-predominant gastritis in gastric cancer prevention. *Archives of Iranian medicine*. 2016;19(2):0-.
8. Afsharzadeh F, Bokharaei-Salim F, Esghaei M, Monavari SH, Merat S, Poustchi H, et al. The presence of autoantibodies to cytoplasmic rod and ring particles in the serum of patients with chronic hepatitis C virus infection. *Hepatitis monthly*. 2016;16(12).
9. Hashempour T, Moayedi J, Musavi Z, Merat S, Alborzi A, Jamalidoust M, et al. ALT Normalization Following Interferon Therapy in HCV Infected Patients. 2015.
10. Hashempour T, Bamdad T, Bergamini A, Lavergne JP, Haj-Sheykholeslami A, Brakier-Gingras L, et al. F protein increases CD4+ CD25+ T cell population in patients with chronic hepatitis C. *Pathogens and disease*. 2015;73(4):ftv022.
11. Haj-Sheykholeslami A, Keshvari M, Sharafi H, Poryasin A, Hemmati K, Mohammadzadehparjikolaei F. Interferon- λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. *World Journal of Gastroenterology: WJG*. 2015;21(29):8935.
12. Carapito R, Poustchi H, Kwemou M, Untrau M, Sharifi A, Merat S, et al. Polymorphisms in EGFR and IL28B are associated with spontaneous clearance in an HCV-infected Iranian population. *Genes & Immunity*. 2015;16(8):514-8.
13. Alborzi A, Hashempour T, Mirhoseini M, Moayedi J, Musavi Z, Merat S, et al. Studying the Frequency of Favorable Allele of rs12979860 Polymorphism of IL-28B in Healthy and HCV Infected Iranian Individuals. *Journal of Fasa University of Medical Sciences*. 2015;5(2):269-77.
14. Ajorloo M, Bamdad T, Hashempour T, Alborzi AM, Mozhgani SHR, Asadi R, et al. Detection of specific antibodies to HCV-ARF/CORE+ 1 protein in cirrhotic and non-cirrhotic

patients with hepatitis C: a possible association with progressive fibrosis. *Archives of Iranian medicine*. 2015;18(5):0-

15. Massarrat S, Haj-Sheykholeslami A, Mohamadkhani A, Zendeheel N, Aliasgari A, Rakhshani N, et al. Pepsinogen II can be a potential surrogate marker of morphological changes in corpus before and after H. pylori eradication. *BioMed research international*. 2014;2014.
16. Mohamadkhani A, Moghaddam SD, Salmanroghani H, Allafsghari A, Yazdanbod A, Mirzaei M, et al. Are the serum biomarkers pepsinogen I and II good predictors for the detection of subjects with atrophic gastritis in areas that have different gastric cancer incidence? *Archives of Iranian medicine*. 2013;16(4):0-
17. Massarrat S, Haj-Sheykholeslami A, Mohamadkhani A, Zendeheel N, Asgari AA, Rakhshani N, et al. Su1981 Pepsinogen II Can Be a Potential Surrogate Marker of Helicobacter pylori-Induced Gastritis, Its Eradication and Mononuclear Cell Corpus Gastritis. *Gastroenterology*. 2013;5(144): S-523.
18. Massarrat S, HAJ SHEYKHOLESLAMI A. Serum pepsinogen ii as a good marker for mass screening and eradication of h. Pylori infection in populations at risk for gastric cancer. *Archives of Iranian medicine*. 2012;15(4):265.
19. Massarrat S, HAJ SA, Mohamadkhani A, Zendeheel N, Rakhshani N, Stolte M, et al. PRECANCEROUS CONDITIONS AFTER H. PYLORI ERADICATION: A RANDOMIZED DOUBLE BLIND STUDY IN FIRST DEGREE RELATIVES OF GASTRIC CANCER PATIENTS. 2012.
20. houshang Sharifi A, Fakharzadeh E, Zamini H, Haj-Sheykholeslami A, Jabbari H. Exacerbation of Skin Lesions in a 50year old Man with Psoriasis during Treatment by Pegylated Interferon. *Middle East Journal of Digestive Diseases (MEJDD)*. 2012;4(1):49-51.
21. Jabbari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E, Shahzamani K, et al. Pegaferon in hepatitis C: Results of a Multicenter Study. *Middle East journal of digestive diseases*. 2011;3(2):110.
22. Zendeheel N, Massarrat S, Sheykholeslami A, Rakhshani N, Saeidi S, Rafiee R, et al. Topography of gastritis and its severity in 864 first degree relatives of gastric cancer patients. *Archives of Iranian medicine*. 2010;13(6):469-75.
23. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline-comparison of three 3-year studies. *Archives of Iranian medicine*. 2010;13(3):177-87.
24. Haj-sheykholeslami A, Rakhshani N, Amirzargar A, Rafiee R, Shahidi SM, Nikbin B, et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. *Clinical Gastroenterology and Hepatology*. 2008;6(2):174-9.
25. Haj-Sheykholeslami A, Bashiri J, Massarrat S. Screening of Gastric Cancer by Serum Pepsinogens and Gastrin17: Abstract no.: P163. *Helicobacter*. 2008;13(5).
26. Haj-sheykholeslami A, Rakhshani N, Amirzargar A, Zendeheel N, Shahidi S, Nikbin B, et al. Serum Biomarkers Pepsinogen I, Pepsinogen II and Gastrin 17 in First Degree Relatives of Gastric Cancer Patients: A Comparative Study with Topography and Grade of Gastritis Abstract no. P167. *Helicobacter*. 2007;12(4):465-6.

27. Talebkhan Y, Mohammadi M, Khalili G, Sheykholeslami A, Rakhshani N, Mahboudi F, et al. Detection of Helicobacter pylori infection by imported IgG ELISA kits in comparison with Iranian home made kit. Govaresh. 2006;11(2):120-5.

28. حاج شیخ الاسلامی, ملارحیمی ملکی, نجومی. مروری بر تاریخچه‌ی شکل‌گیری رشته‌ی تخصصی پزشکی اجتماعی و ضرورت وجودی آن در نظام سلامت. اخلاق و تاریخ پزشکی. ۱۴۰۰؛ ۱۴(۱): ۱۳۹-۲۸